Advertisement
Advertisement

VRDN

VRDN logo

Viridian Therapeutics, Inc. Common Stock

33.65
USD
Sponsored
+0.11
+0.32%
Jan 28, 15:59 UTC -5
Closed
exchange

After-Market

33.62

-0.03
-0.10%

VRDN Earnings Reports

Positive Surprise Ratio

VRDN beat 22 of 38 last estimates.

58%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$12.99M
/
-$1.10
Implied change from Q3 25 (Revenue/ EPS)
-81.60%
/
+223.53%
Implied change from Q4 24 (Revenue/ EPS)
+17935.91%
/
+10.00%

Viridian Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, VRDN reported earnings of -0.34 USD per share (EPS) for Q3 25, beating the estimate of -1.10 USD, resulting in a 69.21% surprise. Revenue reached 70.57 million, compared to an expected 34.59 thousand, with a 203930.30% difference. The market reacted with a +8.29% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -1.10 USD, with revenue projected to reach 12.99 million USD, implying an increase of 223.53% EPS, and decrease of -81.60% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Viridian Therapeutics, Inc. Common Stock reported EPS of -$0.34, beating estimates by 69.21%, and revenue of $70.57M, 203930.3% above expectations.
The stock price moved up 8.29%, changed from $22.55 before the earnings release to $24.42 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 17 analysts, Viridian Therapeutics, Inc. Common Stock is expected to report EPS of -$1.10 and revenue of $12.99M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement